Crossmark Global Holdings Inc. trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 28,278 shares of the pharmaceutical company’s stock after selling 1,014 shares during the period. Crossmark Global Holdings Inc.’s holdings in Vertex Pharmaceuticals were worth $5,450,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of VRTX. Bank of The West lifted its stake in Vertex Pharmaceuticals by 9.8% during the second quarter. Bank of The West now owns 8,892 shares of the pharmaceutical company’s stock valued at $1,511,000 after buying an additional 792 shares in the last quarter. American Research & Management Co. lifted its stake in Vertex Pharmaceuticals by 22.0% during the second quarter. American Research & Management Co. now owns 11,100 shares of the pharmaceutical company’s stock valued at $1,887,000 after buying an additional 2,000 shares in the last quarter. Congress Asset Management Co. MA purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at about $42,954,000. Kaizen Advisory LLC lifted its stake in Vertex Pharmaceuticals by 147.3% during the second quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 358 shares in the last quarter. Finally, First Quadrant L P CA lifted its stake in Vertex Pharmaceuticals by 0.7% during the second quarter. First Quadrant L P CA now owns 192,927 shares of the pharmaceutical company’s stock valued at $32,790,000 after buying an additional 1,298 shares in the last quarter. Institutional investors and hedge funds own 94.95% of the company’s stock.

In related news, CFO Thomas Graney sold 1,076 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $193.24, for a total value of $207,926.24. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Altshuler sold 2,125 shares of the stock in a transaction that occurred on Tuesday, August 28th. The stock was sold at an average price of $181.89, for a total value of $386,516.25. Following the completion of the transaction, the executive vice president now owns 41,238 shares in the company, valued at approximately $7,500,779.82. The disclosure for this sale can be found here. Insiders sold 29,662 shares of company stock worth $5,500,575 in the last 90 days. 0.75% of the stock is currently owned by corporate insiders.

VRTX has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Vertex Pharmaceuticals in a research note on Monday, October 1st. They set an “overweight” rating and a $217.00 price objective for the company. Piper Jaffray Companies reduced their price objective on shares of Vertex Pharmaceuticals to $217.00 and set an “overweight” rating for the company in a research note on Friday, October 26th. Argus upped their price objective on shares of Vertex Pharmaceuticals to $200.00 and gave the company an “average” rating in a research note on Tuesday, August 28th. They noted that the move was a valuation call. Citigroup upped their price objective on shares of Vertex Pharmaceuticals from $203.00 to $206.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Finally, UBS Group upped their price objective on shares of Vertex Pharmaceuticals from $183.00 to $188.00 and gave the company a “neutral” rating in a research note on Thursday, July 26th. Three research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. Vertex Pharmaceuticals currently has an average rating of “Buy” and an average price target of $201.14.

NASDAQ VRTX opened at $159.76 on Wednesday. The company has a quick ratio of 3.59, a current ratio of 3.71 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $42.20 billion, a PE ratio of 199.70, a P/E/G ratio of 1.64 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a 52-week low of $136.50 and a 52-week high of $194.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.07. The business had revenue of $784.54 million during the quarter, compared to analyst estimates of $782.95 million. Vertex Pharmaceuticals had a net margin of 22.87% and a return on equity of 22.92%. During the same period in the prior year, the firm earned $0.53 earnings per share. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 2.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Holdings Reduced by Crossmark Global Holdings Inc.” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/11/21/vertex-pharmaceuticals-incorporated-vrtx-holdings-reduced-by-crossmark-global-holdings-inc.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

See Also: Book Value Per Share – BVPS

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.